Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Histiocytic Neoplasma

  • Stefano A. PileriEmail author
  • Valentina Tabanelli
  • Claudio Agostinelli
Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-28845-1_3863-1

Introduction

In the fourth edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Swerdlow et al. 2017), neoplasms derived from histiocytes and dendritic cells (HDCT) were gathered together based on the functional properties of their normal counterpart (i.e., phagocytosis, processing and presentation of antigens to lymphoid elements, etc.) more than histogenesis. In fact, although most of these elements derive from a common myeloid precursor, some recognize a mesenchymal origin (e.g., follicular dendritic cells). Importantly, HDCT tend to reproduce the morphologic, phenotypic, and ultrastructural characteristics of terminally differentiated elements, i.e., mature histiocytes and different categories of dendritic cells. In line with this, in the fourth edition of the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, blastic plasmacytoid dendritic cell tumor (Swerdlow et al. 2017; Marafioti et al. 2008) was excluded from the HDCT chapter...

This is a preview of subscription content, log in to check access.

References and Further Reading

  1. Allen, C.E, & Parsons, D.W. (2015). Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology, American Society of Hematology Educational Programme, 2015, 559–64.Google Scholar
  2. Badalian-Very, G., Vergilio, J. A., Degar, B. A., Rodriguez-Galindo, C., & Rollins, B. J. (2012). Recent advances in the understanding of Langerhans cell histiocytosis. British Journal of Haematology, 156, 163–172.CrossRefGoogle Scholar
  3. Beasley, M. B. (2010). Smoking-related small airway disease – a review and update. Advances in Anatomic Pathology, 17, 270–276.CrossRefGoogle Scholar
  4. Benharroch, D., Guterman, G., Levy, I., & Shaco-Levy, R. (2010). High content of Langerhans cells in malignant lymphoma – incidence and significance. Virchows Archives, 457, 63–67.CrossRefGoogle Scholar
  5. Boerkamp, K. M., van der Kooij, M., van Steenbeek, F. G., et al. (2013). Gene expression profiling of histiocytic sarcomas in a canine model: The predisposed flatcoated retriever dog. PLoS One, 8, e71094.CrossRefGoogle Scholar
  6. Campochiaro C, Tomelleri A, Cavalli G, et al. (2015). Erdheim-Chester disease. European Journal of Internal Medicine, 26, 223–229.Google Scholar
  7. Chan, J. K., Lamant, L., Algar, E., et al. (2008). ALK+ histiocytosis: A novel type of systemic histiocytic proliferative disorder of early infancy. Blood, 112, 2965–2968.CrossRefGoogle Scholar
  8. Chen, W., Jaffe, R., Zhang, L., et al. (2013). Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: Lineage analysis and BRAF V600E mutation study. North American Journal of Medical Sciences, 5, 386–391.CrossRefGoogle Scholar
  9. Cohen-Aubart, F., Emile, J. F., Maksud, P., et al. (2014). Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology, 83, 1294–1296.CrossRefGoogle Scholar
  10. Dalia, S., Jaglal, M., Chervenick, P., Cualing, H., & Sokol, L. (2014a). Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: The Moffitt cancer center experience over the last twenty-five years. Cancers, 6, 2275–2295.CrossRefGoogle Scholar
  11. Dalia, S., Shao, H., Sagatys, E., Cualing, H., & Sokol, L. (2014b). Dendritic cell and histiocytic neoplasms: Biology, diagnosis, and treatment. Cancer Control, 21, 290–300.CrossRefGoogle Scholar
  12. Donadieu, J., Chalard, F., & Jeziorski, E. (2012). Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opinion on Pharmacotherapy, 13, 1309–1322.CrossRefGoogle Scholar
  13. Falini, B., Pileri, S., De Solas, I., et al. (1990). Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood, 75, 434–444.PubMedGoogle Scholar
  14. Facchetti, F., Pileri, S.A., Lorenzi, L., et al. (2017). Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases. Virchows Archives, 371, 467–489Google Scholar
  15. Feldman, A. L., Arber, D. A., Pittaluga, S., et al. (2008). Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: Evidence for trans-differentiation of the follicular lymphoma clone. Blood, 111, 5433–5439.CrossRefGoogle Scholar
  16. Go, H., Jeon, Y. K., Huh, J., Choi, S. J., Choi, Y. D., Cha, H. J., Kim, H. J., Park, G., Min, S., & Kim, J. E. (2014). Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology, 65, 261–272.CrossRefGoogle Scholar
  17. Griffin, G.K., Sholl, L.M., Lindeman, N.I., et al. (2016). Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-κB regulatory genes. Modern Pathology, 29, 67–74.Google Scholar
  18. Haroche, J., Charlotte, F., Arnaud, L., et al. (2012). High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 120, 2700–2703.CrossRefGoogle Scholar
  19. Hartmann, S., Döring, C., Agostinelli, C., et al. (2016). miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman’s disease. European Journal of Cancer, 64, 159–66.Google Scholar
  20. Idbaih, A., Mokhtari, K., Emile, J. F., et al. (2014). Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology, 83, 1478–1480.CrossRefGoogle Scholar
  21. Juvet, S. C., Hwang, D., & Downey, G. P. (2010). Rare lung diseases III: Pulmonary Langerhans’ cell histiocytosis. Canadian Respiratory Journal, 17, e55–e62.CrossRefGoogle Scholar
  22. Kairouz, S., Hashash, J., Kabbara, W., McHayleh, W., & Tabbara, I. A. (2007). Dendritic cell neoplasms: An overview. American Journal of Hematology, 82, 924–928.CrossRefGoogle Scholar
  23. Kansal, R., Quintanilla-Martinez, L., Datta, V., Lopategui, J., Garshfield, G., & Nathwani, B. N. (2013). Identification of the V600D mutation in exon 15 of the BRAF oncogene in congenital, benign Langerhans cell histiocytosis. Genes, Chromosomes and Cancer, 52, 99–106.CrossRefGoogle Scholar
  24. Laginestra, M.A., Tripodo, C., Agostinelli, C., et al. (2017). Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of follicular dendritic cell sarcomas. Molecular Cancer Research, 5, 541–52.Google Scholar
  25. Lorenzi, L., Lonardi, S., Petrilli, G., et al. (2012). Folliculocentric B-cell-rich follicular dendritic cells sarcoma: A hitherto unreported morphological variant mimicking lymphoproliferative disorders. Human Pathology, 43, 209–215.CrossRefGoogle Scholar
  26. Marafioti, T., Paterson, J. C., Ballabio, E., et al. (2008). Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood, 111, 3778–3792.CrossRefGoogle Scholar
  27. Méhes, G., Irsai, G., Bedekovics, J., et al. (2014). Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: Demonstration by allele-specific PCR/direct sequencing and immunohistochemistry. American Journal of Surgical Pathology, 38, 1644–1648.CrossRefGoogle Scholar
  28. O’Malley, D. P., Zuckerberg, L., Smith, L. B., et al. (2014). The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases. Annals of Diagnostic Pathology, 18, 18–20.CrossRefGoogle Scholar
  29. Ohtake, H., & Yamakawa, M. (2013). Interdigitating dendritic cell sarcoma and follicular dendritic cell sarcoma: Histopathological findings for differential diagnosis. Journal of Clinical and Experimental Hematopathology, 53, 179–184.CrossRefGoogle Scholar
  30. Perkins, S. M., & Shinohara, E. T. (2013). Interdigitating and follicular dendritic cell sarcomas: A SEER analysis. American Journal of Clinical Oncology, 36, 395–398.CrossRefGoogle Scholar
  31. Pileri, S., & Falini, B. (1990). Peripheral T-cell lymphoma associated with hemophagocytic syndrome and hemophagocytic lymphohistiocytosis of children: Do they share something? Blood, 76, 2163–2164.Google Scholar
  32. Pileri, S. A., Grogan, T. M., Harris, N. L., et al. (2002). Tumours of histiocytes and accessory dendritic cells: An immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology, 41, 1–29.CrossRefGoogle Scholar
  33. Ratei, R., Hummel, M., Anagnostopoulos, I., et al. (2010). Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans’ cell sarcoma: Evidence for hematopoietic plasticity. Haematologica, 95, 1461–1466.CrossRefGoogle Scholar
  34. Rezk, S. A., Nathwani, B. N., Zhao, X., & Weiss, L. M. (2013). Follicular dendritic cells: Origin, function, and different disease-associated patterns. Human Pathology, 44, 937–950.CrossRefGoogle Scholar
  35. Roden, A. C., Hu, X., Kip, S., et al. (2014). BRAF V600E expression in Langerhans cell histiocytosis: Clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. American Journal of Surgical Pathology, 38, 548–551.CrossRefGoogle Scholar
  36. Sahm, F., Capper, D., Preusser, M., et al. (2012). BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood, 120, e28–e34.CrossRefGoogle Scholar
  37. Saygin, C., Uzunaslan, D., Ozguroglu, M., Senocak, M., & Tuzuner, N. (2013). Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series. Critical Reviews in Oncology/Hematology, 88, 253–271.CrossRefGoogle Scholar
  38. Schuerfeld, K., Lazzi, S., de Santi, M. M., Gozzetti, A., Leoncini, L., & Pileri, S. A. (2003). Cytokeratin-positive interstitial cell neoplasm: A case report and classification issues. Histopathology, 43, 491–494.CrossRefGoogle Scholar
  39. Shao, H., Xi, L., Raffeld, M., Feldman, A. L., et al. (2011). Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: A study of seven cases. Modern Pathology, 24, 1421–1432.CrossRefGoogle Scholar
  40. Suárez-Vilela, D., Izquierdo, F. M., Méndez-Alvarez, J. R., & Escobar-Stein, J. (2012). Neoplasms of dendritic cells: Related cell origins and diagnostic markers. Fibroblastic reticulum cells and fibroblastic reticulum cell tumors show several immunophenotypic profiles. Human Pathology, 43, 1530–1531.CrossRefGoogle Scholar
  41. Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., & Thiele, J. (Eds.). (2017). WHO classification of tumours of haematopoietic and lymphoid tissue. Revised 4th edition. Lyon: IARC Press. Chapter 17.Google Scholar
  42. Takahashi, E., & Nakamura, S. (2013). Histiocytic sarcoma: An updated literature review based on the 2008 WHO classification. Journal of Clinical and Experimental Hematopathology, 53, 1–8.CrossRefGoogle Scholar
  43. Vermi, W., Lonardi, S., Bosisio, D., et al. (2008). Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. Journal of Pathology, 216, 356–364.CrossRefGoogle Scholar
  44. Weiss, G. J., Alarcon, A., Halepota, M., Penny, R. J., & Von Hoff, D. D. (2010). Molecular characterization of interdigitating dendritic cell sarcoma. Rare Tumors, 2, e50.CrossRefGoogle Scholar
  45. Wilejto, M., & Abla, O. (2012). Langerhans cell histiocytosis and Erdheim-Chester disease. Current Opinion in Rheumatology, 24, 90–96.CrossRefGoogle Scholar
  46. Yousem, S. A., Dacic, S., Nikiforov, Y. E., & Nikiforova, M. (2013). Pulmonary Langerhans cell histiocytosis: Profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest, 143, 1679–1684.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Stefano A. Pileri
    • 1
    • 2
    Email author
  • Valentina Tabanelli
    • 2
  • Claudio Agostinelli
    • 3
  1. 1.Bologna UniversityBolognaItaly
  2. 2.European Institute of OncologyMilanItaly
  3. 3.Department of Experimental, Diagnostic and Specialty MedicineBologna University School of MedicineBolognaItaly